

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Wei Gu**

Application No.:

Group No.: **N/A**

Filed: **Herewith**

Examiner: **N/A**

For:

NOVEL G-PROTEIN COUPLED RECEPTORS AND USES THEREFOR

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements
2. Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) (8 pages)
- 3.. Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No. EI992152667US

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.



Signature

Date: September 18, 2003

Sean Hunziker

(type or print name of person certifying)

Practitioner's Docket No. MPI99-037P1RCP1CN1M

Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted


This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No.: 09/851,595, filed on May 8, 2001.

The following references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, in the event additional copies are necessary, the undersigned will submit such copies upon request.

September 18, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By _____



Kerri Pollard Schray
Registration No. 47,066
75 Sidney Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Compl te if Kn wn	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	1	of	7	Attorney Docket Number	MPI99-037P1RCP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.
	C1	Ashburner M., et al., Genetics 153 :179-219 (1999)
	C2	Copy of BLAST Search (Patent_2/gsnuc database) using the hLGR6 nucleotide sequence
	C3	Copy of BLAST Search (Patent_2/PatentDbPreviewNuc database) using the hLGR6 nucleotide sequence
	C4	Copy of BLAST Search (Patent_2/FastAlert_N.txt database) using the hLGR6 nucleotide sequence
	C5	Copy of BLAST Search (Patent_2/FastAlert_P.txt database) using the hLGR amino acid sequence
	C6	Copy of BLAST Search (Patent_2/gsprot database) using the hLGR amino acid sequence
	C7	Copy of BLAST Search (NRN/nuc database) using the hLGR nucleotide sequence
	C8	Copy of BLAST Search (NRO/protot database) using the hLGR amino acid sequence
	C9	DGENE Accession No. 1998N-V56989 for Human sperm surface protein I-23 cDNA
	C10	DGENE Accession No. 1999P-W93889 for Human HG38 protein
	C11	DGENE Accession No. 1999P-W93890 for Human HG3 protein
	C12	DGENE Accession No. 1999P-W93904 for Human AOMF05 protein
	C13	DGENE Accession No. 1999P-W93905 for Human AOMF05 protein
	C14	DGENE Accession No. 1999P-W93906 for Human AOMF05 protein

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				C <i>mpl te if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
<i>(use as many sheets as necessary)</i>					
Sheet	2	of	7	Attorney Docket Number	MPI99-037P1RCP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	
	C15	DGENE Accession No. 1999P-W93965 for Human AOMF05 protein	
	C16	DGENE Accession No. 1999N-X23980 for Human HG38DNA	
	C17	DGENE Accession No. 1999N-X23981 for Human HG38 protein	
	C18	DGENE Accession No. 1999P-Y42168 for Human LGR4 protein sequence	
	C19	DGENE Accession No. 1999P-Y42169 for Human LGR5 protein SEQUENCE	
	C20	DGENE Accession No. 1999P-Y53574 for Human gonadotropin receptor partial sequence #4	
	C21	DGENE Accession No. 1999P-Y53575 for Human gonadotropin receptor partial sequence #5	
	C22	DGENE Accession No. 1999N-Z25343 for Human LGR4 nucleotide sequence	
	C23	DGENE Accession No. 1999N-Z25344 for Human LGR5 nucleotide sequence	
	C24	DGENE Accession No. 1999N-Z40457 for Human gonadotropin receptor partial coding sequence #1	
	C25	DGENE Accession No. 1999N-Z40460 for Human gonadotropin receptor partial coding sequence #4	
	C26	DGENE Accession No. 1999N-Z40461 for Human gonadotropin receptor partial coding sequence #5	
	C27	DGENE Accession No. 1999N-Z40463 for Human gonadotropin receptor partial coding sequence #7	
	C28	Dohlman H., <i>Annu. Rev. Biochem.</i> 60:653-688 (1991)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	3	of	7	Attorney Docket Number	MPI99-037P1RCP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.			
	C29	Dufau M., <i>Annu. Rev. Physiol.</i> 60:461-496 (1998)			
	C30	Database EMBL 'Online! EBI; entry A1831861, accession number A1831861, 13 July 1999 (1999-07-13) NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP): Homo sapiens cDNA clone similar to orphan G protein-coupled receptor HG38" XP002187010 mRNA sequence			
	C31	Database EMBL 'Online! EBI; entry HSC1SG111, accession number Z44115, 6 November 1994 (1994-11-06) GENEEXPRESS: "H. sapiens partial cDNA sequence" XP002187011 cDNA sequence			
	C32	GenBank Accession No. AF061444 for Homo Sapiens G protein-coupled receptor LGR5 (LGR5) mRNA			
	C33	GenBank Accession No. AF061443 for Rattus norvegicus G protein-coupled receptor LGR4 (LGR4) mRNA			
	C34	GenBank Accession No. AF062006 for Homo Sapiens orphan G protein-coupled receptor HG38 mRNA			
	C35	GenBank Accession No. AF088074 for Homo Sapiens full length insert cDNA clone ZD96CO1			
	C36	GenBank Accession No. P35379 for Follicle stimulating hormone receptor precursor (FSH-R) (Follitropin receptor)			
	C37	GenBank Accession No. P49059 for Follicle stimulating hormone receptor precursor (FSH-R) (Follitropin receptor)			
	C38	GenBank Accession No. P47799 for Follicle stimulating hormone receptor precursor (FSH-R) (Follitropin receptor)			
	C39	GenBank Accession No. AAB07030 for FSH-TSH			
	C40	GenBank Accession No. AAF44846 for hypothetical protein [Drosophila melanogaster]			
	C41	GenBank Accession No. G51804 for SHGC-79247 Human Homo sapiens STS genomic, sequence tagged site			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Compl te if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	
				Filing Date	Herewith
				First Named Inventor	Wei Gu
				Group Art Unit	N/A
				Examiner Name	N/A
Sheet	4	of	7	Attorney Docket Number	MPI99-037P1RCP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		T ²
	C42	GenBank Accession No. AF110818 for <i>Mus musculus</i> orphan G protein-coupled receptor FEX mRNA		
	C43	GenBank Accession No. AAC77910 for G protein-coupled receptor LGR4 [<i>Rattus norvegicus</i>]		
	C44	GenBank Accession No. JG0193 for G protein-coupled receptor FEX – mouse		
	C45	GenBank Accession No. AAD14684 for orphan G protein-coupled receptor FEX [<i>Mus musculus</i>]		
	C46	GenBank Accession No. AAC77911 for G protein-coupled receptor LGR5 [<i>Homo sapiens</i>]		
	C47	GenBank Accession No. AAC28019 for orphan G protein-coupled receptor HG38 [<i>Homo sapiens</i>]		
	C48	Gutkind J. Silvio, <i>The Journal of Biological Chemistry</i> 273(4):1839-1842 (1998)		
	C49	Hermey G. et al., <i>Biochemical and Biophysical Research Communications</i> 254:273-279 (1999)		
	C50	Holtzman E. J., et al., <i>Human Molecular Genetics</i> 2(8) :1201-1204 (1993)		
	C51	Hsu S. Y., et al., <i>Molecular Endocrinology</i> 12 :1830-1845 (1998)		
	C52	Ji T. H. et al., <i>Recent Progress in Hormone Research</i> 52:431-454 (1997)		
	C53	Juppner H. et al., <i>Science</i> 254 :1024-1026 (1991)		
	C54	Khan H. et al., <i>Biochemical and Biophysical Research Communications</i> 190(3) :888-894 (1993)		
	C55	Klein P. S. et al., <i>Science</i> 241:1467-1472 (1988)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	
Sheet	5	of	7	Filing Date	Herewith
				First Named Inventor	Wei Gu
				Group Art Unit	N/A
				Examiner Name	N/A
				Attorney Docket Number	MPI99-037P1RCP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.
	C56	Kohn L. D., et al., <i>Vitamins and Hormones</i> 50 :287-384 (1995)
	C57	Kurjan J., <i>Annu. Rev. Biochem.</i> 61:1097-1129 (1992)
	C58	Lin H. Y., et al., <i>Science</i> 254:1022-1024 (1991)
	C59	McDonald T., et al., <i>Biochemical and Biophysical Research Communications</i> 247 :266-270 (1998)
	C60	McKusick V. A. et al., <i>J. Med. Genet.</i> 30:1-26 (1993)
	C61	Mikayana et al., <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:10056-10060 (1993)
	C62	Nakanishi S., <i>Science</i> 258:597-603 (1992)
	C63	Nathans J. et al., <i>Annu. Rev. Genet.</i> 26:403-424 (1992)
	C64	Remy J. J. et al., <i>Gene</i> 163:257-261 (1995)
	C65	Reppert et al., GenBank Accession No. U52218, July 28, 1996
	C66	Reppert et al., GenBank Accession No. U52219, July 28, 1996
	C67	Reppert et al., <i>FEBS Lett.</i> 386:219-224 (1996)
	C68	Reppert, S. M., et al., <i>FEBS Lett.</i> 386(2-3):219-224 (1996)
	C69	Robert P. et al., <i>Biochemical and Biophysical Research Communications</i> 201(1):201-207 (1994)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	6	of	7	Attorney Docket Number	MPI99-037P1RCP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		T ²
	C70	Rodan, <i>Bone</i> 13:S3-S6 (1992)		
	C71	Roth et al., <i>J. Biol. Chem.</i> 31:22041-22047 (1999)		
	C72	Selbie L. A., <i>TiPS</i> 19:87-93 (1998)		
	C73	Sheau Yu Hsu et al. "The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): Identification of LGR6 and LGR7 and the signaling mechanism for LGR7" <i>Molecular Endocrinology</i> 14(8):1257-1271 (August 2000)		
	C74	Simoni M. et al., <i>Endocrine Reviews</i> 18(6):739-773 (1997)		
	C75	Skolnick et al., <i>Nature Biotechnology</i> 18:283-287 (2000)		
	C76	Spiegel A. M. et al., <i>The Journal of Clinical Investigation</i> 92:1119-1125 (1993)		
	C77	<i>Stedman's Medical Dictionary</i> , Physicians' Desk Reference, Medical Economics Company Inc. (2002)		
	C78	Stein, W. D., <i>Channels, Carriers, and Pumps : An Introduction to Membrane Transport</i> , Academic Press 1st Ed. Chapter 3:Ion Channels Across Cell Membranes:73-125 (1990)		
	C79	Strader C. D. et al., <i>Annu. Rev. Biochem.</i> 63:101-132 (1994)		
	C80	Voet et al., <i>Biochemistry – John Wiley & Sons, Inc.</i> :126-128 and 228-236 (1990)		
	C81	Weaver and Reppert, <i>NeuroReport</i> 9:109-112 (1996)		
	C82	Wiren et al., <i>J. Endocrinol.</i> 175(3):683-694 (2002)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Compl t if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	7	of	7	Attorney Docket Number	MPI99-037P1RCP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.			T ²
	C83	Yarney T. A. et al., <i>Molecular and Cellular Endocrinology</i> 93:219-226 (1993)			
Examiner Signature		Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<i>Compl te if Known</i>	
				Application Number	
				Filing Date	Herewith
				First Named Inventor	Wei Gu
				Group Art Unit	N/A
				Examiner Name	N/A
Sheet	1	of	1	Attorney Docket Number	MPI99-037P1RCP1CN1M

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Code ⁵ Office ³	Kind Number ⁴ (if known)				
	B1	WO	98/36771		8/98		
	B2	WO	99/15545		4/99		
	B3	WO	99/15660		4/99		
	B4	WO	99/48921		9/99		
	B5	EP	0 950 711		10/99		
	B6	WO	99/63088		12/99		
	B7	WO	00/04140		1/00		
	B8	WO	00/12708		3/00		
	B9	WO	00/15796		3/00		
	B10	WO	00/15797		3/00		
	B11	WO	01/36473		5/01		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.